These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 17360103

  • 1. Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study.
    Di Lorenzo G, Autorino R, Perdonà S, De Laurentiis M, D'Armiento M, Cancello G, Mirone V, Imbimbo C, Longo N, Altieri V, Tortora G, Figg WD, De Placido S.
    Eur Urol; 2007 Oct; 52(4):1020-7. PubMed ID: 17360103
    [Abstract] [Full Text] [Related]

  • 2. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
    Efstathiou E, Bozas G, Kostakopoulos A, Kastritis E, Deliveliotis C, Antoniou N, Skarlos D, Papadimitriou C, Dimopoulos MA, Bamias A.
    Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
    [Abstract] [Full Text] [Related]

  • 3. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
    Ross RW, Beer TM, Jacobus S, Bubley GJ, Taplin ME, Ryan CW, Huang J, Oh WK, Prostate Cancer Clinical Trials Consortium.
    Cancer; 2008 Feb 01; 112(3):521-6. PubMed ID: 18085595
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.
    Rosenberg JE, Weinberg VK, Kelly WK, Michaelson D, Hussain MH, Wilding G, Gross M, Hutcheon D, Small EJ.
    Cancer; 2007 Aug 01; 110(3):556-63. PubMed ID: 17577218
    [Abstract] [Full Text] [Related]

  • 7. Docetaxel-based chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: factors predicting response and survival.
    Nayyar R, Sharma N, Gupta NP.
    Int J Urol; 2009 Sep 01; 16(9):726-31. PubMed ID: 19769656
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Combination chemotherapy with docetaxel, vinorelbine and estramustine phosphate in metastatic androgen-resistant prostate cancer: a single institution experience.
    Pectasides D, Pectasides E, Papaxoinis G, Koumarianou A, Psyrri A, Xiros N, Tountas N, Kamposioras K, Papatsibas G, Floros T, Gouveris P, Karageorgopoulou S, Economopoulos T.
    Anticancer Res; 2009 Feb 01; 29(2):769-75. PubMed ID: 19331234
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A prospective, open label, randomized phase II trial of weekly docetaxel versus weekly vinorelbine as first line chemotherapy in patients with androgen independent prostate cancer.
    Krainer M, Tomek S, Elandt K, Horak P, Albrecht W, Eisenmenger M, Höltl W, Schramek P, Stackl W, Zielinski C, Reibenwein J.
    J Urol; 2007 Jun 01; 177(6):2141-5; discussion 2145. PubMed ID: 17509302
    [Abstract] [Full Text] [Related]

  • 13. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer.
    Nelius T, Klatte T, Yap R, Kalinski T, Röpke A, Filleur S, Allhoff EP.
    BJU Int; 2006 Sep 01; 98(3):580-5. PubMed ID: 16925757
    [Abstract] [Full Text] [Related]

  • 14. Docetaxel, estramustine and prednisone for hormone-refractory prostate cancer: a single-center experience.
    Boehmer A, Anastasiadis AG, Feyerabend S, Nagele U, Kuczyk M, Schilling D, Corvin S, Merseburger AS, Stenzl A.
    Anticancer Res; 2005 Sep 01; 25(6C):4481-6. PubMed ID: 16334130
    [Abstract] [Full Text] [Related]

  • 15. Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer.
    Joshua AM, Nordman I, Venkataswaran R, Clarke S, Stockler MR, Boyer MJ.
    Intern Med J; 2005 Aug 01; 35(8):468-72. PubMed ID: 16176469
    [Abstract] [Full Text] [Related]

  • 16. Phase II trial of vinorelbine and estramustine in the treatment of metastatic hormone-resistant prostate cancer.
    Borrega P, Velasco A, Bolaños M, del Mar Perez M, Mel JR, Reina JJ, Rodríguez-Jaraiz MA, Chaves M, González-Barón M.
    Urol Oncol; 2004 Aug 01; 22(1):32-5. PubMed ID: 14969801
    [Abstract] [Full Text] [Related]

  • 17. A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer.
    Ferrero JM, Foa C, Thezenas S, Ronchin P, Peyrade F, Valenza B, Lesbats G, Garnier G, Boublil JL, Tchiknavorian X, Chevallier D, Amiel J.
    Oncology; 2004 Aug 01; 66(4):281-7. PubMed ID: 15218295
    [Abstract] [Full Text] [Related]

  • 18. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
    James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T, Phung D, Dawson NA.
    Eur Urol; 2009 May 01; 55(5):1112-23. PubMed ID: 19042080
    [Abstract] [Full Text] [Related]

  • 19. Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer.
    Nelius T, Reiher F, Lindenmeir T, Klatte T, Rau O, Burandt J, Filleur S, Allhoff EP.
    Onkologie; 2005 Nov 01; 28(11):573-8. PubMed ID: 16249643
    [Abstract] [Full Text] [Related]

  • 20. Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis.
    Hahn NM, Marsh S, Fisher W, Langdon R, Zon R, Browning M, Johnson CS, Scott-Horton TJ, Li L, McLeod HL, Sweeney CJ.
    Clin Cancer Res; 2006 Oct 15; 12(20 Pt 1):6094-9. PubMed ID: 17062685
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.